Beth Israel Deaconess Medical Center
Latest From Beth Israel Deaconess Medical Center
French biotech expands fibrosis partnership with Boehringer Ingelheim, and a co-development pact with AbbVie around ROR gamma inverse agonists. Helsinn signs on to detail Novartis' Zykadia in the US.
With no end in sight for the obesity epidemic, there is a vast and underserved market opportunity for manufacturers developing minimally invasive solutions for obesity that can fill the treatment gap between invasive bariatric surgery and conservative weight loss methods (diet, exercise, and drugs). Despite some high-profile setbacks in the last few years, the market for minimally invasive bariatric devices is gaining steam as several companies have recently launched obesity devices on the US market while others have completed clinical trials and are advancing toward US regulatory approval.
Flagship Ventures has recruited former Merck Chief Medical Officer Michael Rosenblatt as its CMO to mentor biopharma startups in the venture firm's portfolio – a hire that appears to be the first of its kind.
With three to four years in the books, Big Pharma’s updated tie-ups with academia have started to progress – some have even reached first-in-human stages, but these updated models have yet to produce any radical results that show they are an improvement over old-style partnerships.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.